FY2025 EPS Estimates for Henry Schein, Inc. Reduced by Analyst (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC - Free Report) - Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Henry Schein in a report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $5.56 per share for the year, down from their prior forecast of $5.63. Leerink Partnrs has a "Market Perform" rating on the stock. The consensus estimate for Henry Schein's current full-year earnings is $5.07 per share. Leerink Partnrs also issued estimates for Henry Schein's FY2026 earnings at $6.06 EPS and FY2027 earnings at $6.61 EPS.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The business's quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.21 EPS.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. upped their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the company an "overweight" rating in a research note on Wednesday, March 6th. Barrington Research upped their price target on Henry Schein from $90.00 to $92.00 and gave the company an "outperform" rating in a research report on Wednesday. UBS Group cut their price objective on Henry Schein from $82.00 to $80.00 and set a "neutral" rating on the stock in a research report on Wednesday. Evercore ISI upped their target price on Henry Schein from $79.00 to $83.00 and gave the company an "in-line" rating in a report on Wednesday, February 28th. Finally, Jefferies Financial Group lifted their price target on shares of Henry Schein from $74.00 to $81.00 and gave the company a "hold" rating in a report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $81.73.

Henry Schein Trading Up 0.9 %

NASDAQ HSIC traded up $0.68 during trading on Thursday, hitting $73.44. 1,306,126 shares of the company's stock traded hands, compared to its average volume of 1,110,417. Henry Schein has a 12-month low of $60.01 and a 12-month high of $82.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The stock has a fifty day moving average of $73.01 and a two-hundred day moving average of $72.34. The firm has a market cap of $9.44 billion, a P/E ratio of 23.18, a PEG ratio of 1.68 and a beta of 0.87.

Insider Activity

In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the business's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares of the company's stock, valued at approximately $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Institutional Investors Weigh In On Henry Schein

Several institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Vanguard Group Inc. grew its stake in shares of Henry Schein by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 15,171,464 shares of the company's stock valued at $1,148,632,000 after purchasing an additional 161,891 shares during the period. JPMorgan Chase & Co. grew its position in Henry Schein by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company's stock valued at $353,898,000 after buying an additional 53,506 shares during the period. American Century Companies Inc. increased its holdings in Henry Schein by 7.3% during the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company's stock valued at $350,392,000 after buying an additional 322,649 shares during the last quarter. Boston Partners raised its position in Henry Schein by 144.1% in the fourth quarter. Boston Partners now owns 2,637,429 shares of the company's stock worth $199,393,000 after acquiring an additional 1,556,831 shares during the period. Finally, Fiduciary Management Inc. WI boosted its stake in shares of Henry Schein by 17.1% during the 4th quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company's stock worth $172,947,000 after acquiring an additional 333,855 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.